Table 3 Multivariate analysis of prognostic markers in the whole group.

Whole cohort		HR (95% CI)	P value^b
Model 1
Minimal TFD (I)		0.85 (0.77; 0.94)	0.002
Number of positive LN		1.14 (1.05; 1.23)	0.001
Model 2
TFD (I) binarised^a	≤3.5 (ref. >3.5)	4.58 (1.52; 13.80)	0.007
LN positivity	Yes (ref. no)	3.79 (1.83; 7.81)	<0.001
Model 3
TFD (I) binarised^a	≤3.5 (ref. >3.5)	4.57 (1.50; 13.97)	0.008
LN positivity	Yes (ref. no)	3.76 (1.67; 8.50)	0.001
LVSI	Yes (ref. no)	1.01 (0.45; 2.28)	0.976
Model 4
TFD (I) binarised^a	≤3.5 (ref. >3.5)	3.48 (0.71; 17.00)	0.123
LN positivity	Yes (ref. no)	5.02 (2.26; 11.14)	<0.001
Stromal invasion (P)		1.00 (0.94; 1.07)	0.989
Model 5
TFD (I) binarised^a	≤3.5 (ref. >3.5)	4.13 (1.16; 14.69)	0.029
LN positivity	Yes (ref. no)	3.8 (1.82; 7.92)	<0.001
Tumour type	Adeno (ref. squamo)	1.39 (0.26; 7.49)	0.700
	Adenosquamo (ref. squamo)	1.24 (0.2; 7.78)	0.816
Model 6
Largest tumour size (P) binarised^a	>32.5 (ref. ≤32.5)	2.29 (1.16; 4.49)	0.016
LN positivity	Yes (ref. no)	3.78 (1.94; 7.36)	<0.001

adeno adenocarcinoma, CI confidence interval, LN lymph node, LVSI lymphovascular space invasion, squamo squamous cell cancer, TFD tumour-free distance, (I) assessed by imaging, (P) assessed by pathology.
^aCut-off determined by ROC analysis, the criterion was the highest value of the sum of sensitivity and specificity. ^blevel of significance P < 0.05.

Quick links

Search